CS logo
small CS logo
ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico

Napoli, Campania, Italy
Istituto di ricerca a Napoli

About ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


"Il Pascale è il maggiore IRCCS Oncologico del Mezzogiorno ed è Centro di Riferimento per la rete oncologica nazionale e regionale. L'Istituto persegue finalità di ricerca prevalentemente clinica, e di ricerca applicata nel campo biomedico e in quello dell'organizzazione e gestione dei servizi sanitari, dedicando grande impegno alle problematiche più ampie del paziente oncologico, che vanno dall'assistenza psicologica ai problemi nutrizionali, alla terapia del dolore, alle cure palliative in genere, fino alle fasi più delicate della malattia."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
11
Total Rows: 1

Clinical Trials at ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


During the past decade, ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 YearsStarted TrialsCompleted Trails
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
2012-10-22
2016-04-28
Completed
208
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
2015-10-05
2022-06-14
Completed
809
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
2015-07-28
2019-01-15
Completed
152
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
2016-11-30
2022-12-12
Completed
1,005
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
2017-01-10
2022-12-20
Completed
772
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2017-03-08
2022-08-12
Completed
1,301
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
2017-06-30
2023-12-31
Active, not recruiting
1,101
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
2020-06-30
2023-07-15
Active, not recruiting
172

Rows per page:

1–11 of 11

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "GOG Foundation" with 2 trials as a collaborator, "Chugai" with 1 trials as a collaborator and "Exelixis" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.
Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 11Hoffmann-La Roche: 11

Created with Highcharts 11.1.0Top CollaboratorsEuropean Network ofGynaecologicalOncological Trial Groups(ENGOT): 2European Network ofGynaecologicalOncological Trial Groups(ENGOT): 2GOG Foundation: 2GOG Foundation: 2Chugai: 1Chugai: 1Exelixis: 1Exelixis: 1

Clinical Trials Conditions at ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


According to Clinical.Site data, the most researched conditions in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are "Ovarian Cancer" (3 trials), "Cervical Cancer" (2 trials), "Carcinoma, Renal Cell" (1 trials), "Carcinoma, Transitional Cell" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" in a lesser frequency.

Clinical Trials Intervention Types at ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


Most popular intervention types in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (8 trials), "Bevacizumab" (3 trials), "Paclitaxel" (3 trials), "Placebo" (3 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

Clinical Trials Genders at ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


The vast majority of trials in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" are 5 trials for "Female" genders, 4 trials for "All" genders and 2 trials for "Male" genders.

Clinical Trials Status at ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico


Currently, there are NaN active trials in "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, undefined suspended trials, and undefined terminated clinical trials to date.
Out of the total trials that were conducted in ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 8Phase 3: 8Phase 2: 3Phase 2: 3

Created with Highcharts 11.1.0Trials StatusCompleted: 6Completed: 6Active, not recruiting: 3Active, not recruiting: 3Recruiting: 2Recruiting: 2